Eli Lilly and Co | 8-K: Eli Lilly Announces Anat - Ashkenazi to Resign as Executive Vice President and Chief Financial Officer
Eli Lilly and Co | 8-K: Chief Financial Officer Anat Ashkenazi Resigns
Eli Lilly and Co | 8-K: Voting Results of Annual Shareholders' Meeting
Eli Lilly and Co | 8-K: Eli Lilly and Co Reports First-Quarter 2024 Financial Results
Eli Lilly and Co | DEFA14A: Others
Eli Lilly and Co | DEF 14A: Definitive information statements
Eli Lilly and Co | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Eli Lilly and Co | 8-K: Entry into an Underwriting Agreement
Eli Lilly and Co | 8-K: Eli Lilly and Co Reports Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
Eli Lilly and Co | 8-K: Eli Lilly and Co Reports Third Quarter 2023 Financial Results
Eli Lilly and Co | 8-K: Eli Lilly and Co Reports Second-Quarter 2023 Financial Results
Eli Lilly and Co | 8-K: Voting results 2023 Annual Meeting of Shareholders
Eli Lilly and Co | 8-K: Eli Lilly and Co Reports First-Quarter 2023 Financial Results
Eli Lilly and Co | DEFA14A: Others
Eli Lilly and Co | DEF 14A: Definitive proxy statements
Eli Lilly and Co | 8-K: Eli Lilly entered into a non-competition agreement with Daniel Skovronsky
Eli Lilly and Co | 8-K: Eli Lilly and Co entered into an underwriting agreement
Eli Lilly and Co | PRE 14A: Preliminary proxy statement not related to a contested matter or merger/acquisition
Eli Lilly and Co | 8-K: Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook
Eli Lilly and Co | 8-K: Eli Lilly and Co Announces 2023 Financial Guidance and Plans to Launch up to Four New Medicines
No Data